BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 15160930)

  • 1. Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy.
    Tsutsumi Y; Kawamura T; Saitoh S; Yamada M; Obara S; Miura T; Kanamori H; Tanaka J; Asaka M; Imamura M; Masauzi N
    Leuk Lymphoma; 2004 Mar; 45(3):627-9. PubMed ID: 15160930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
    Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
    Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma.
    Cho Y; Yu SJ; Cho EJ; Lee JH; Kim TM; Heo DS; Kim YJ; Yoon JH
    J Med Virol; 2016 Jun; 88(6):1010-7. PubMed ID: 26531242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lamivudine prophylaxis prevents hepatitis B virus reactivation in anti-HBc positive patients under rituximab for non-Hodgkin lymphoma.
    Loglio A; Viganò M; Grossi G; Labanca S; Goldaniga M; Pompa A; Farina L; Rumi M; Corradini P; Facchetti F; Lunghi G; Baldini L; Lampertico P
    Dig Liver Dis; 2019 Mar; 51(3):419-424. PubMed ID: 30316785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma.
    Tsutsumi Y; Tanaka J; Kawamura T; Miura T; Kanamori H; Obara S; Asaka M; Imamura M; Masauzi N
    Ann Hematol; 2004 Jan; 83(1):58-60. PubMed ID: 14513286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylaxis of hepatitis B reactivation using lamivudine in a patient receiving rituximab.
    Hamaki T; Kami M; Kusumi E; Ueyama J; Miyakoshi S; Morinaga S; Mutou Y
    Am J Hematol; 2001 Dec; 68(4):292-4. PubMed ID: 11754421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Precore mutant hepatitis B reactivation after treatment with CHOP-rituximab.
    Zell JA; Yoon EJ; Ignatius Ou SH; Hoefs JC; Chang JC
    Anticancer Drugs; 2005 Jan; 16(1):83-5. PubMed ID: 15613909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection.
    Yang HC; Tsou HH; Pei SN; Chang CS; Chen JH; Yao M; Lin SJ; Lin J; Yuan Q; Xia N; Liu TW; Chen PJ; Cheng AL; Hsu C;
    J Hepatol; 2018 Aug; 69(2):286-292. PubMed ID: 29551710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy.
    Niitsu N; Hagiwara Y; Tanae K; Kohri M; Takahashi N
    J Clin Oncol; 2010 Dec; 28(34):5097-100. PubMed ID: 20837949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations.
    Law JK; Ho JK; Hoskins PJ; Erb SR; Steinbrecher UP; Yoshida EM
    Leuk Lymphoma; 2005 Jul; 46(7):1085-9. PubMed ID: 16019563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin's lymphomas: high prevalence of acquired viral genomic mutations.
    Picardi M; Pane F; Quintarelli C; De Renzo A; Del Giudice A; De Divitiis B; Persico M; Ciancia R; Salvatore F; Rotoli B
    Haematologica; 2003 Nov; 88(11):1296-303. PubMed ID: 14607759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hepatitis B virus reactivation after cessation of prophylaxis with lamivudine in a patient with non-Hodgkins lymphoma treated with chemotherapy and rituximab].
    Vives S; Sancho JM; Planas R; Ribera JM
    Med Clin (Barc); 2006 Jun; 127(1):39. PubMed ID: 16796944
    [No Abstract]   [Full Text] [Related]  

  • 13. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.
    Yeo W; Chan TC; Leung NW; Lam WY; Mo FK; Chu MT; Chan HL; Hui EP; Lei KI; Mok TS; Chan PK
    J Clin Oncol; 2009 Feb; 27(4):605-11. PubMed ID: 19075267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of prophylactic lamivudine to prevent hepatitis B virus reactivation in B-cell lymphoma treated with rituximab-containing chemotherapy.
    Wang YH; Fan L; Wang L; Zhang R; Xu J; Fang C; Li JY; Xu W
    Support Care Cancer; 2013 May; 21(5):1265-71. PubMed ID: 23151650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study.
    Seto WK; Chan TS; Hwang YY; Wong DK; Fung J; Liu KS; Gill H; Lam YF; Lie AK; Lai CL; Kwong YL; Yuen MF
    J Clin Oncol; 2014 Nov; 32(33):3736-43. PubMed ID: 25287829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy.
    Viganò M; Mangia G; Lampertico P
    Expert Opin Biol Ther; 2014 Jul; 14(7):1019-31. PubMed ID: 24909454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A case of drug-induced liver injury caused by entecavir for treatment of hepatitis B virus reactivation during RCHOP in a patient with non-Hodgkin lymphoma].
    Kondo M; Kitada N; Kobayashi M; Morita S; Yoshioka M; Tsuji T; Mori A; Okamoto T; Watari M
    Gan To Kagaku Ryoho; 2009 Jul; 36(7):1199-201. PubMed ID: 19620818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reactivation of lamivudine-resistant occult hepatitis B in an HIV-infected patient undergoing cytotoxic chemotherapy.
    Schnepf N; Sellier P; Bendenoun M; Zini JM; Sanson-le Pors MJ; Mazeron MC
    J Clin Virol; 2007 May; 39(1):48-50. PubMed ID: 17368969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP.
    Dai MS; Chao TY; Kao WY; Shyu RY; Liu TM
    Ann Hematol; 2004 Dec; 83(12):769-74. PubMed ID: 15338194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Impending liver failure after chemoimmunotherapy-induced reactivation of hepatitis B - successful treatment with entecavir].
    Lock G; Helmich F; Bertram M
    Dtsch Med Wochenschr; 2012 Jun; 137(23):1248-50. PubMed ID: 22644491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.